Clinical Trial: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123454) titled 'A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma' on July 24.

Brief Summary: This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: B-cell Non-Hodgkin Lymphoma

Intervention: DRUG: AZD4512

AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) tha...